← All Cardinal Health INC filings

Cardinal Health INC 8-K filings

NYSE
CAH
Cardinal Health INC
8-K: Cardinal Health Realigns Reporting Segments, Provides Recast Financials
Cardinal Health has updated its organizational structure and realigned its operating segments, providing recast financial results for fiscal years 2022, 2023, and the first two quarters of 2024.
NYSE
CAH
Cardinal Health INC
8-K: Cardinal Health Loses OptumRx Contract, Reaffirms Fiscal 2024 Guidance and Long-Term Targets
Cardinal Health announced the nonrenewal of its pharmaceutical distribution contracts with OptumRx, while reaffirming its fiscal 2024 non-GAAP EPS guidance and long-term financial targets.
NYSE
CAH
Cardinal Health INC
8-K: Cardinal Health Appoints Robert Azelby to Board of Directors
Cardinal Health has elected Robert Azelby, a seasoned biopharmaceutical executive, to its Board of Directors, effective March 1, 2024.
NYSE
CAH
Cardinal Health INC
8-K: Cardinal Health Issues $1.15 Billion in Senior Notes
Cardinal Health has successfully priced and issued $1.15 billion in senior notes, split between 2029 and 2034 maturities.
NYSE
CAH
Cardinal Health INC
8-K: Cardinal Health Exceeds Expectations, Raises Fiscal 2024 Outlook After Strong Q2 Performance
Cardinal Health reported a 12% increase in revenue and raised its fiscal year 2024 outlook, driven by strong growth in both its Pharmaceutical and Medical segments.